The CEO of drugmaker Eli Lilly said that Medicare’s coverage of Ozempic and other GLP-1s could have major impacts on weight loss treatment options. Specifically, it will help Eli Lilly launch a brand new obesity pill, orforglipron. According to the Centers for Disease Control and Prevention, 41.9 percent of U.S. adults were obese from 2017 to 2020, and roughly 9.2 percent of U.S. adults fit the criteria for severe obesity. GLP-1s, which help treat type 2 diabetes and can also help patients lose